PHRMA(ON BEHALF OF WE WORK FOR HEALTH)

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2009–2021

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2021	—	3	1
2020	—	4	1
2019	—	4	1
2018	—	4	1
2017	—	4	1
2016	—	6	1
2015	—	4	1
2014	—	4	1
2013	—	4	1
2012	—	4	1
2011	—	4	1
2010	—	4	1
2009	—	4	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
RANDOLPH E. CLOUD & ASSOCIATES	—	53

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	52
HOUSE OF REPRESENTATIVES	51

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	51
Pharmacy	Pharmacy	2

Bills Explicitly Cited (9)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3590110th Congress

American Middle Class Tax (AMT) Relief Act of 2007

2010 · first_quarter · Firm: RANDOLPH E. CLOUD & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Follow on Biologics provisions in HR3590, HR1427, and HR1548, also Health Care and Education Reconcilation Act of 2010

Client expense: — · Firm income: $10,000

Matched citations: HR3590

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2010 · first_quarter · Firm: RANDOLPH E. CLOUD & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Follow on Biologics provisions in HR3590, HR1427, and HR1548, also Health Care and Education Reconcilation Act of 2010

Client expense: — · Firm income: $10,000

Matched citations: HR1427

H.R. 1548111th Congress

Pathway for Biosimilars Act

2010 · first_quarter · Firm: RANDOLPH E. CLOUD & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

Follow on Biologics provisions in HR3590, HR1427, and HR1548, also Health Care and Education Reconcilation Act of 2010

Client expense: — · Firm income: $10,000

Matched citations: HR1548

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · fourth_quarter · Firm: RANDOLPH E. CLOUD & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

America's Healthy Future Act of 2009- issues related to importation of pharmaceutical products from foreign countries. -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics; -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1427

Show 5 more cited filings

H.R. 1548111th Congress

Pathway for Biosimilars Act

2009 · fourth_quarter · Firm: RANDOLPH E. CLOUD & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

America's Healthy Future Act of 2009- issues related to importation of pharmaceutical products from foreign countries. -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics; -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1548

S. 726111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · fourth_quarter · Firm: RANDOLPH E. CLOUD & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

America's Healthy Future Act of 2009- issues related to importation of pharmaceutical products from foreign countries. -H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval for follow-on biologics, including provisions on data exclusivity and patient procedures for biologics; -H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; -S. 726, Promoting Innovation and Access to Life-Saving Medicines Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics

Client expense: — · Firm income: $20,000

Matched citations: S. 726

H.R. 1427111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · second_quarter · Firm: RANDOLPH E. CLOUD & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1427- Promoting Innovation and Access to Life-Saving Medicine Act : regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics (continued on separate page) H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1427

H.R. 1548111th Congress

Pathway for Biosimilars Act

2009 · second_quarter · Firm: RANDOLPH E. CLOUD & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1427- Promoting Innovation and Access to Life-Saving Medicine Act : regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics (continued on separate page) H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.

Client expense: — · Firm income: $20,000

Matched citations: H.R. 1548

S. 726111th Congress

Promoting Innovation and Access to Life-Saving Medicine Act

2009 · second_quarter · Firm: RANDOLPH E. CLOUD & ASSOCIATES

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 1427- Promoting Innovation and Access to Life-Saving Medicine Act : regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics (continued on separate page) H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics.

Client expense: — · Firm income: $20,000

Matched citations: S. 726

Source: Senate LDA

PHRMA(ON BEHALF OF WE WORK FOR HEALTH) — Lobbying Disclosure | Poliscope